Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa
Phase of Trial: Phase 0
Latest Information Update: 06 Jun 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- 31 May 2019 Status changed from recruiting to completed.
- 15 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
- 07 Apr 2017 New trial record